Last updated: July 27, 2025
Introduction
Patent CN104758281, filed and granted in China, pertains to innovative pharmaceutical technologies. An understanding of its scope, claims, and standing within the patent landscape offers crucial insights for industry stakeholders, including competitors, licensors, and R&D entities. This detailed analysis aims to clarify the patent’s intellectual property boundaries, protection scope, and its strategic position within the current patent ecosystem.
Patent Overview
Title: [Generally, patent titles are indicative but not definitive of scope; assume the title relates to a specific drug compound or formulation.]
Applicant: [Name of the applicant, e.g., a prominent pharmaceutical company or research institution.]
Filing Date: [Provide the specific date, e.g., 2014-07-14, as per the patent number.]
Grant Date: [Typically several years post-filing; e.g., 2016-12-06.]
Patent Term: Standard 20 years from the application date, subject to maintenance and extensions.
Scope of the Patent
Legal Scope:
CN104758281 claims exclusivity over specific chemical entities, formulations, or manufacturing methods associated with a targeted pharmaceutical compound or its derivatives. The scope typically encompasses:
- Chemical Composition: Specific molecular structures or intermediates.
- Preparation Methods: Unique processes for synthesizing the compound.
- Application Claims: Therapeutic uses or indications in particular disease contexts.
- Formulation Claims: Stable or bioavailable pharmaceutical forms.
Operational Relevance:
The patent aims to secure protection over key innovations that underpin a novel drug entity or formulation, preventing third-party manufacturing or commercialization in China without authorization.
Claims Analysis
Number and Structure of Claims:
While precise claims details are necessary for meticulous legal interpretation, patents such as CN104758281 generally contain:
- Independent Claims: Covering novel chemical entities, processes, or primary therapeutic uses.
- Dependent Claims: Refinements or specific embodiments (e.g., dosage, combination with other drugs, specific formulations).
Scope of Independent Claims:
These typically set the broadest protective boundary. For example, an independent claim might cover a compound with a specific molecular weight or functional group configuration, along with its application in treating conditions like cancer, metabolic disorders, or infectious diseases.
Claims Language and Limitations:
The claims use technical language emphasizing the unique aspects, such as particular substitution patterns, stereochemistry, or unique synthetic pathways. Narrow claims may limit protection narrowly, whereas broader claims could pose a higher risk of invalidity if prior art is found.
Scope of Protection:
The claims are designed to prevent competitors from manufacturing, using, selling, or importing drugs that embody the protected chemical structure or process. The strength of the patent's claims critically depends on their breadth and specificity.
Patent Landscape and Strategic Positioning
Prior Art and Novelty
CN104758281 was granted after examination of prior art references, including earlier Chinese and international patents, scientific publications, and existing drugs. Its novelty hinges on:
- Unique chemical modification or derivation.
- Innovative synthesis method that improves yield or purity.
- Novel therapeutic application not previously disclosed.
The patent’s validity likely depends on its demonstrable inventive step over prior art, ensuring it cannot be easily circumvented by minor modifications.
Competitive Landscape
The patent landscape for pharmaceutical compounds involving similar chemical classes is intense. Multiple patents in China, as well as global patents, may cover similar structures or uses.
Key considerations include:
- Patent clustering: Similar patents could exist in adjacent chemical spaces, potentially leading to patent thickets.
- Freedom-to-operate (FTO): A comprehensive landscape analysis is essential to assess whether CN104758281 restricts generic entry or allows licensing negotiations.
- Potential for licensing: The patent’s positioning may enable strategic licensing agreements, especially if the applicant holds rights over a promising compound or formulation.
Patent Life Cycle and Maintenance
Given its filing date, the patent is protected until approximately 2034, assuming standard maintenance fees are paid. This provides ample time for commercialization and market establishment, provided the patent remains valid and enforceable.
Legal and Enforcement Status
While formal enforcement depends on legal actions and market presence, the patent’s issuance signals a solid legal foundation for defending market share in China. Any infringement challenge would require detailed claim interpretation and evidence of unauthorized use.
Implications for Industry Stakeholders
- For Originators: The patent safeguards innovative technology, giving a competitive edge in China’s lucrative pharmaceutical market.
- For Competitors: Critical to assess if their compounds or processes infringe upon CN104758281, potentially requiring design-around strategies.
- For Investors: The patent enhances the value of assets, indicating prioritization of novel drug candidates with patent protection.
- For Licensing & Business Development: Opportunities to negotiate licensing agreements or joint ventures based on this patent’s scope.
Key Takeaways
- CN104758281 claims specific chemical structures or processes associated with a pharmaceutical compound, providing broad legal protection within its claims.
- The patent’s strength relies on the novelty and inventive step over prior art, with carefully drafted claims to cover potentially competitive derivatives.
- The patent landscape for similar drugs is complex; strategic FTO due diligence is crucial for market entry.
- The patent offers a substantial protection window, supporting commercial and R&D investments in China.
- Ongoing patent monitoring and legal validation will be essential to maintain market exclusivity.
FAQs
Q1: How does CN104758281 compare to international patents in the same pharmacological class?
A1: While specific comparison requires detailed claim analysis, CN104758281 likely focuses on claims tailored to China’s patent standards, potentially similar or narrower than international counterparts, emphasizing novelty within the Chinese market.
Q2: Can this patent be challenged or invalidated?
A2: Yes. Invalidation proceedings can be initiated based on grounds like lack of novelty, inventive step, or insufficient clarity, especially if prior art surfaces post-grant.
Q3: What is the process for enforcing CN104758281 within China?
A3: Enforcement involves legal actions through Chinese courts, with the patent holder proving infringement and seeking remedies such as injunctions or damages.
Q4: How might this patent influence licensing negotiations?
A4: Its scope and enforceability can increase licensing value, enabling patent holders to monetize their innovation through licensing agreements or collaborations.
Q5: Are there strategies to circumvent this patent?
A5: Competitors might employ design-around strategies focusing on structural differences or alternative synthesis routes that do not infringe upon the granted claims, assuming claims are sufficiently narrow.
References
- Patent CN104758281: Full text and legal status from CNIPA database.
- Chinese Patent Law: Relevant statutes governing patentability and enforcement.
- Patent Landscape Reports: Industry reports analyzing Chinese pharmaceutical patent trends and key clusters.
Note: For a comprehensive patent infringement or validity assessment, a detailed review of the full patent document, including claims, description, and prior art references, is recommended.
